SCHEMBL589864

SCHEMBL589864

O=Nc1ccc2c(O)ccc(N=O)c2c1O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
KDM4E B2RXH2 1/20 0.41
NPC1 O15118 1/20 0.41
ALDH1A1 P00352 1/20 0.41
XBP1 P17861 1/20 0.41
RAB9A P51151 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
APP P05067 1/20 0.37
THRB P10828 1/20 0.37
HPGD P15428 1/20 0.37
ALOX15 P16050 1/20 0.37
TSHR P16473 1/20 0.37
CASP1 P29466 1/20 0.37
SNCA P37840 1/20 0.37
RECQL P46063 1/20 0.37
HSD17B10 Q99714 1/20 0.37
ATIC P31939 1/20 0.35
PIM1 P11309 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2914893 0.77 TDP1 (0.44) MAPTTDP1KDM4ENPC1ALDH1A1
SCHEMBL3078639 0.75 MAPT (0.42) MAPTTDP1KDM4ENPC1ALDH1A1
SCHEMBL12955990 0.75 TDP1 (0.42) MAPTTDP1KDM4ENPC1ALDH1A1
SCHEMBL3087121 0.74 ALDH1A1 (0.39) MAPTTDP1KDM4ENPC1ALDH1A1
SCHEMBL2602613 0.71 MAPT (0.40) MAPTTDP1KDM4ENPC1ALDH1A1
SCHEMBL1032621 0.70 IDO1 (0.59) MAPTTDP1KDM4ENPC1ALDH1A1
SCHEMBL1002641 0.70 KDM4E (0.39) MAPTTDP1KDM4ENPC1ALDH1A1
SCHEMBL9296302 0.70 RPS6KA3 (0.42) MAPTTDP1KDM4ENPC1ALDH1A1
SCHEMBL11783112 0.69 CTSB (0.51) MAPTTDP1KDM4ENPC1ALDH1A1
SCHEMBL22170101 0.66 HSD17B10 (0.50) MAPTTDP1ALDH1A1L3MBTL1APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12163968-B2 Preparation of nucleated RBC (NRBC) analogs for use as reference hematology controls in automated hematology analyzers BIO-RAD LABORATORIES, INC. (US) 2024-12-10 US claimed
US-12163968-B2 Preparation of nucleated RBC (NRBC) analogs for use as reference hematology controls in automated hematology analyzers BIO-RAD LABORATORIES, INC. (US) 2024-12-10 US disclosed
EP-4208021-A1 PREPARATION OF NUCLEATED RBC (NRBC) ANALOGS FOR USE AS REFERENCE HEMATOLOGY CONTROLS IN AUTOMATED HEMATOLOGY ANALYZERS Bio-Rad Laboratories, Inc. (US) 2023-07-12 EP disclosed
CN-116097093-A Preparation of Nucleated RBC (NRBC) analogs for use as reference blood controls in automated blood analyzers 生物辐射实验室股份有限公司 2023-05-09 CN disclosed
WO-2022051443-A1 PREPARATION OF NUCLEATED RBC (NRBC) ANALOGS FOR USE AS REFERENCE HEMATOLOGY CONTROLS IN AUTOMATED HEMATOLOGY ANALYZERS BIO-RAD LABORATORIES, INC. (US) 2022-03-10 WO disclosed
US-20220065878-A1 PREPARATION OF NUCLEATED RBC (NRBC) ANALOGS FOR USE AS REFERENCE HEMATOLOGY CONTROLS IN AUTOMATED HEMATOLOGY ANALYZERS BIO-RAD LABORATORIES, INC. 2022-03-03 US disclosed
EP-2376908-B1 SIMULATION OF NORMAL FRESH BLOOD PLATELETS BIO RAD LABORATORIES (US) 2014-12-31 EP disclosed
CN-102341701-B Mimetics of normal fresh platelets BIO RAD LABORATORIES 2014-07-09 CN disclosed
US-8114580-B2 Simulation of normal fresh blood platelets for reference control BIO-RAD LABORATORIES, INC. (US) 2012-02-14 US disclosed
EP-2376908-A1 SIMULATION OF NORMAL FRESH BLOOD PLATELETS Bio-Rad Laboratories, Inc. (US) 2011-10-19 EP disclosed
WO-2010083130-A1 SIMULATION OF NORMAL FRESH BLOOD PLATELETS BIO-RAD LABORATORIES, INC. (US) 2010-07-22 WO disclosed
US-20100178647-A1 SIMULATION OF NORMAL FRESH BLOOD PLATELETS BIO-RAD LABORATORIES, INC. (US) 2010-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100178647-A1 SIMULATION OF NORMAL FRESH BLOOD PLATELETS MPL, THPO, PFKP MAPT 4876/4885TDP1 2078/4885KDM4E 3264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.